204 related articles for article (PubMed ID: 17283449)
1. New therapies in multiple myeloma.
Merchionne F; Perosa F; Dammacco F
Clin Exp Med; 2007 Sep; 7(3):83-97. PubMed ID: 17972050
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
Voorhees PM; Manges RF; Sonneveld P; Jagannath S; Somlo G; Krishnan A; Lentzsch S; Frank RC; Zweegman S; Wijermans PW; Orlowski RZ; Kranenburg B; Hall B; Casneuf T; Qin X; van de Velde H; Xie H; Thomas SK
Br J Haematol; 2013 May; 161(3):357-66. PubMed ID: 23432640
[TBL] [Abstract][Full Text] [Related]
3. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
Stein R; Smith MR; Chen S; Zalath M; Goldenberg DM
Clin Cancer Res; 2009 Apr; 15(8):2808-17. PubMed ID: 19351768
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.
Yoshizawa K; Mukai HY; Miyazawa M; Miyao M; Ogawa Y; Ohyashiki K; Katoh T; Kusumoto M; Gemma A; Sakai F; Sugiyama Y; Hatake K; Fukuda Y; Kudoh S
Cancer Sci; 2014 Feb; 105(2):195-201. PubMed ID: 24329927
[TBL] [Abstract][Full Text] [Related]
5. [Multiple Myeloma Treatment Guidelines by the Portuguese Group of Multiple Myeloma].
João C; Bergantim R; Santos J; Afonso C; Bernardo P; Coelho H; Costa C; Esteves G; Freitas JG; Gerivaz R; Jorge A; Macedo A; Montalvão A; Neves M; Pedrosa CL; Pereira S; Roque A; Seabra P; M Silva H; Silveira MP; Tomé A; Trigo F; Sarmento AB; Lúcio P; Geraldes C;
Acta Med Port; 2023 Jul; 36(7-8):517-526. PubMed ID: 37429590
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
Minarik J; Pavlicek P; Pour L; Pika T; Maisnar V; Spicka I; Jarkovsky J; Krejci M; Bacovsky J; Radocha J; Straub J; Kessler P; Wrobel M; Walterova L; Sykora M; Obernauerova J; Brozova L; Gregora E; Adamova D; Gumulec J; Adam Z; Scudla V; Hajek R;
PLoS One; 2015; 10(4):e0123866. PubMed ID: 25875484
[TBL] [Abstract][Full Text] [Related]
7. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
8. USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma.
Meng J; Ai X; Lei Y; Zhong W; Qian B; Qiao K; Wang X; Zhou B; Wang H; Huai L; Zhang X; Han J; Xue Y; Liang Y; Zhou H; Chen S; Sun T; Yang C
Theranostics; 2019; 9(2):573-587. PubMed ID: 30809294
[No Abstract] [Full Text] [Related]
9. Drug Discovery by Molecular Imaging and Monitoring Therapy Response in Lymphoma.
Kalimuthu S; Jeong JH; Oh JM; Ahn BC
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749424
[TBL] [Abstract][Full Text] [Related]
10. Elevated calpain activity in acute myelogenous leukemia correlates with decreased calpastatin expression.
Niapour M; Farr C; Minden M; Berger SA
Blood Cancer J; 2012 Jan; 2(1):e51. PubMed ID: 22829235
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NF-κB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice.
Liang Y; Seymour RE; Sundberg JP
J Invest Dermatol; 2011 Jan; 131(1):141-9. PubMed ID: 20811394
[TBL] [Abstract][Full Text] [Related]
12. Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.
Lee S; Yagita H; Sayers TJ; Celis E
Cancer Immunol Immunother; 2010 Jul; 59(7):1073-81. PubMed ID: 20213120
[TBL] [Abstract][Full Text] [Related]
13. Successful mobilization of peripheral blood stem cells with bortezomib + high-dose cyclophosphamide + G-CSF in a light chain myeloma patient after failure with Total Therapy 2.
Giglio G; Romito S; Carrozza F; Musacchio M; Antuzzi G; Gigli R; Magri M; Bavaro P; Di Bartolomeo P; Dell'Isola M; Accorsi P
Int J Hematol; 2009 Jul; 90(1):81-86. PubMed ID: 19529980
[TBL] [Abstract][Full Text] [Related]
14. Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53.
Dayal S; Sparks A; Jacob J; Allende-Vega N; Lane DP; Saville MK
J Biol Chem; 2009 Feb; 284(8):5030-41. PubMed ID: 19098288
[TBL] [Abstract][Full Text] [Related]
15. A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma.
Shu ST; Nadella MV; Dirksen WP; Fernandez SA; Thudi NK; Werbeck JL; Lairmore MD; Rosol TJ
Cancer Res; 2007 Dec; 67(24):11859-66. PubMed ID: 18089816
[TBL] [Abstract][Full Text] [Related]
16. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
[TBL] [Abstract][Full Text] [Related]
17. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Richardson P; Jagannath S; Colson K
Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
